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Serogroup A of Neisseria meningitidis is the organism responsible for causing epidemic diseases in developing
countries by a pilus-mediated adhesion to human brain endothelial cells. Type IV pilus assembly protein (PilF)
associated with bacterial adhesion, aggregation, invasion, host cell signaling, surface motility, and natural transformation
can be considered as a candidate for effective anti-meningococcal drug development. Since the crystal structure of PilF
was not available, in the present study, it was modeled after the Z2491 strain (CAM09255.1) using crystal structure of
chain A of Vibrio cholerae putative Ntpase EpsE (Protein Data Bank (PDB) ID: 1P9R) and then we based this analysis on
sequence comparisons and structural similarity using in silico methods and docking processes, to design a suitable
inhibitor molecule. The ligand 3-{(4S)-5-{[(1R)-1-cyclohexylethyl]amino}-4-[(5S)-5-(prop-2-en-1-yl) cyclopent-1-en-1-yl]-
1,4-dihydro-7H-pyrrolo[2,3-d] pyrimidin-7-yl}-1,2-dideoxy-b-L-erythro-hex-1-en-3-ulofuranosyl binds to the protein with
a binding energy of −8.10 kcal and showed a drug likeness of 0.952 with no predicted health hazard. It can be utilized
as a potent inhibitor of N. meningitidis pilus-mediated adhesion to human brain endothelial cells preventing meningeal
colonization.
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ADME analysisIntroduction
Neisseria meningitidis or meningococcus known for causing
meningitis and other forms of meningococcal diseases is
one of the prime causes of child mortality in industrialized
countries and epidemics in Asian and African countries. N.
meningitidis is an aerobic, gram-negative, non-endospore
forming, non-motile (although has pilus), coccal parasitic
bacterium [1]. Most strangely, this bacterium thrives in the
human throat commensally and colonizes in a distinct
number of populations as a healthy carrier [2]. Of the five
common serogroups (A, B, C, Y, W135) responsible for
about 90% of infections, serogroups A, B, and C account
for most cases throughout the world, with the serogroup A
strain responsible for epidemic diseases in developing
countries [2,3]. The strain Z2491 [GenBank: CAM09255.1]
is included under serogroup A.* Correspondence: kirtisnigdha@gmail.com; ptsonis1@udayton.edu
†Equal contributors
1Department of Biology, University of Dayton, Dayton, OH, USA
Full list of author information is available at the end of the article
© 2015 Mehta et al.; licensee BioMed Central.
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.N. meningitidis has shown widespread resistance to
the currently used drugs and thus demands an advanced
drug strategy to combat it. New drug targets will be
helpful in the discovery of more diverse and potent
drugs. Mainly, enzymes involved in macromolecular and
metabolite synthesis appear to be promising potential
targets, few of which have already been validated in many
microorganisms. The two component signal transduction
systems of bacteria which enable it to sense, respond, and
adapt to their environmental or intracellular state varia-
tions are quite essential for the growth and survival in ad-
verse environmental conditions. This system is ubiquitous
in bacteria and has been reported to be involved in viru-
lence. The translocation of proteins that is associated with
the virulence factors across the outer membrane is sup-
ported by the type II secretion pathway. For the pathogen-
specific type II secretion pathway, five virulent factors i.e.,
type IV pilus assembly protein (PilF), pilus assemblyThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Mehta et al. Human Genomics  (2015) 9:5 Page 2 of 9protein (PilG), twitching motility protein1 (PilT-1), twitch-
ing motility protein2 (PilT-2), and competence protein
(comA) are found to be involved. However, the major
components of the secretion pathway are type IV pilus as-
sembly proteins. Type IV pili are responsible for bacterial
adhesion, aggregation, invasion, host cell signaling, surface
motility, and natural transformation [4]. As reported by
Coureuil et al. [5] the initiation of signaling cascades by
meningococcus follows the pilus-mediated adhesion to
human brain endothelial cells that eventually leads to
opening of intercellular junctions and allows meningeal
colonization. Hence, for the development of an effective
anti-meningococcal drug, type IV pilus assembly protein
(PilF) can serve as a potential target [3].
Since the crystal structure of PilF was not available,
the present study was conducted to model after the
Z2491 strain using the crystal structure of chain A of
Vibrio cholerae Putative Ntpase EpsE [PDB: 1P9R] as a
template and then using in silico methods and docking
processes. Thus, a suitable inhibitor molecule has beenFigure 1 Structural evaluation of PilF protein. Secondary sequence alignme
ncbi.nlm.nih.gov/Blast.cgi] against the Protein Data Bank database [http://ww
the crystal structure of chain A of Vibrio cholerae Putative Ntpase EpsE [PDBdesigned. Further, this molecule has been checked for its
possible health effects and drug likeness using bioinfor-
matic tools.
Methods
Sequence alignment and structure prediction
The FASTA sequence of the target protein type IV pilus
assembly protein (PilF) of the Neisseria meningitidis
Z2491 strain [GenBank: CAM09255.1] was retrieved from
the NCBI Entrez sequence search [http://www.ncbi.nlm.
nih.gov]. Following the BLASTp run [http://blast.ncbi.
nlm.nih.gov/Blast.cgi] against the Protein Data Bank data-
base [http://www.rcsb.org/pdb/], the crystal structure of
chain A of Vibrio cholerae Putative Ntpase EpsE [PDB:
1P9R] was selected as a template sequence. The 3D struc-
ture of the query protein was predicted by the automated
homology modeling program, Modeller 9.10 [6]. For mod-
eling, the template and target sequences were carefully
aligned to remove potential alignment errors. Structural
models were visualized by Swiss Pdb Viewer (SPDBV)nt between CAM09255.1 and 1P9R by the BLASTp run [http://blast.
w.rcsb.org/pdb/]. It provided with maximum identity score and hence
: 1P9R] was selected as a template sequence.
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of the model was performed by the Ramachandran
plot analysis [7], using SPDBV and the online tool,
PROCHECK [8] [http://nihserver.mbi.ucla.edu/SAVES/].
Further evaluation was carried out using ProSA-web
[https://prosa.services.came.sbg.ac.at/prosa.php] and Veri-
fy_3D [http://nihserver.mbi.ucla.edu/SAVES/].
Active site, lead prediction, and ligand building
The active domains of the developed model were deter-
mined using the software LIGSITEcsc [9] [http://projects.
biotec.tu-dresden.de/pocket/]. LIGSITEcsc is a web server
for the automatic identification of pockets on a protein
surface using the Connolly surface and the degree of
conservation. From the study of interaction between
different chemical components of ligands with type II
secretion system in bacteria, a potential lead molecule
was determined and modified using ChemSketch ver-
sion 12.01 [http://www.acdlabs.com], which was then
integrated with a modeled protein structure using the
Hex 6.3 [http://hex.loria.fr/]. Hex is an interactive pro-
tein docking and molecular superposition program.
The protein-lead complex was then used to develop the lig-
and using the software LigBuilder version 1.3 [http://www.
chem.ac.ru/Chemistry/Soft/LIGBUILD.en.html], which is a
general-purpose program package written for a structure-
based drug-design procedure. Based on the 3D structure
of the target protein, it can automatically build ligand
molecules within the binding pocket.Figure 2 Homology modeling. (a) 3D structure of 1P9R and (b) theoreticaAutodocking
The ligands developed were chosen for docking studies.
The docking study was carried out using the AutoDock
software version 1.5.4, which uses genetic algorithm (GA).
PilF [GenBank: CAM09255.1] was loaded into AutoDock
Tools (ADT) [http://autodock.scripps.edu/resources] as a
receptor and made ready for docking by the addition of
charges and hydrogen which any PDB file of the mol-
ecule usually does not contain, using the edit option
in ADT. All the ligands were separately and individu-
ally docked with the PilF model; a grid for dock search
was built for the whole molecule to find the most
probable binding site in CAM09255.1 and to measure
its interaction parameters with the ligands. The dock-
ing process was carried out in the default parameters
of ADT.
ADME and toxicity analysis
The absorption, digestion, metabolism, and excretion
(ADME) properties are directly related to the bio-
logical effect of drugs and their fate in an organism
and therefore need to be evaluated in medicinal chemis-
try. The ADME properties and its possible effects on
health are determined using different bioinformatic tools
like Molinspiration [http://www.molinspiration.com/],
PASS (Prediction of Activity Spectra for Substances)
[http://www.genexplain.com/pass], ACD/Labs I-Lab 2.0
[http://www.acdlabs.com/resources/ilab/index.php], and
Toxtree [10].l model of PilF (CAM 09255.1) obtained after homology modeling.
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of important molecular properties (logP, polar surface
area, number of hydrogen bond donors and acceptors,
and others) as well as prediction of bioactivity score
for the most important drug targets (GPCR ligands,
kinase inhibitors, ion channel modulators, nuclear
receptors).
Results and discussion
Structural evaluation of PilF protein
Structural information about the type IV pilus assembly
protein (PilF) of the Neisseria meningitidis Z2491strain
is currently unavailable. The present study reports the
homology modeling and structural interaction between
type IV pilus assembly protein of the Neisseria meningi-
tidis Z2491 strain with an inhibitor. Chain A of Vibrio
cholerae putative Ntpase Epse [PDB: 1P9R] having a
high degree of homology with CAM09255.1 was used as
a template with an identity of 45% (and conserved amino
acid change of 63%). Its x-ray crystal structure has anFigure 3 Ramachandran plot of the model. Validation of the model was d
version v 4.0.4 [http://www.expasy/spdbv.org]. Good overall stereochemistr
falling in the most favored regions and 10.3% in the allowed region.atomic resolution of 2.50 Å and an R value of 0.217. The
secondary structure alignment obtained between the
query and template sequence is shown in Figure 1. Based
on the Discrete Optimized Protein Energy (DOPE) score,
the selected model with minimum score is shown in
Figure 2b. Root mean square deviation (RMSD) value of a
C alpha carbon atom between the template and predicted
model was found to be 2.49A• determined by using the
SPDBV software. The predicted model was subjected to
PROCHECK analysis to determine psi and phi torsion
angles. Good overall stereochemistry is obtained for the
model with 89.1% of the residue psi/phi angles falling in
the most favored regions and 10.3% in the allowed region.
The Ramachandran plot is shown in Figure 3. The G-
factors indicating the quality of covalent and bond angle
distance were −0.25 for dihedrals, 0.19 for covalent, and
overall −0.07. The interaction energy per residue is also
calculated by program PROSA and Verify_3D. Figure 4
displays the PROSA profile calculated for the PilF model.
The comparable Ramachandran plot characteristics andone by Ramachandran plot analysis using Swiss PDB Viewer (SPDBV)
y is obtained for the model with 89.1% of the residue psi/phi angles
Figure 4 PROSA energy plot. Interaction energy per residue is
calculated by program PROSA.
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(Table 1).Functional site prediction, lead identification, and ligand
generation
The software LIGSITEcsc was utilized for functional site
prediction. On the basis of interaction with the surround-
ing atoms, out of the three pockets predicted as shown in
Figure 5, the pocket PKT 1032 with the best interaction
result was identified as the possible functional site of the
protein molecule. The molecule 7-[5-O-(hydroxy{[hydro-
xyl(phosphonooxy)phosphoryl]oxy}phosphoryl)pentofura-
nosyl]-7H-pyrrolo[2,3-d]pyrimidin-5-amine (Figure 6) was
identified as the lead based on the interaction studyTable 1 Validation statistics for theoretical model of PilF
by PROCHECK analysis
Plot statistics
Residues in the most favored regions [A,B,L] 304 89.1%
Residues in additional allowed regions [a,b,l,p] 35 10.3%
Residues in generously allowed regions [~a,~b,~l,~p] 2 0.6%
Residues in disallowed regions 0 0.0%
Number of non-glycine and non-proline residues 341 100.0%
Number of end-residues (exd. Gly and Pro) 2
Number of glycine residues 28
Number of proline residues 17
Total number of residues 388between different chemical components of ligands with
the type II secretion system in bacteria. Using the Hex
6.3 [http://hex.loria.fr/], it was introduced into the pro-
tein binding site. The ten best ligands were selected for
docking out of the many ligands developed by the soft-
ware LigBuilder based on the Lipinski’s “Rule of 5”
properties [11].
Docking study
Docking was performed using AutoDock Tools-1.5.4 for
the receptor of 1P9R with all the ten ligands loaded indi-
vidually into ADT to analyze ten best conformations. The




furanosyl (C28H44N4O3) with PilF protein has a binding
energy of −8.10 kcal M −1 and inhibitory constant of 1.16
μM. It was concluded to be the best docked ligand mol-
ecule in comparison to other nine molecules. The ligand
molecule after docking is shown in Figure 7b. The PilF
protein and docked ligand in the pocket is shown in
Figure 7c.
ADME and toxicity analysis of the ligand
The pharmacokinetic features of the ligand taken into
account in this work were preliminarily investigated. It is
extremely advantageous if information about the ADME
properties of the studied molecules could be produced
in the early stages of the drug discovery process. The
use of in silico methods to predict ADME properties is
intended as a first step in this direction, and the results
of such an analysis are herein reported and discussed.




predicted by the Molinspiration property engine v2011.04
and ACD/Labs I-Lab 2.0 were found to be in accord-
ance with the Lipinski’s “Rule of 5” properties [11],
which states, that most “drug-like” molecules have logP
<= 5, molecular weight < = 500, number of hydrogen
bond acceptors <= 10, and number of hydrogen bond
donors <= 5. The bioactivity of the ligand was predicted
using Molinspiration Bioactivity engine v2011.06 (Tables 2
and 3). Oral bioavailability as determined by ACD/Labs I-
Lab was between 30%–70%. Drug likeness of the ligand
was found to be very high i.e., 0.952 calculated by PASS
(http://www.ibmc.msk.ru/PASS/). Moreover, no toxic or
harmful effect of the ligand over human health was pre-
dicted by PASS and Toxtree (http://toxtree.sourceforge.
net/) software. Possible health effects of the ligand mol-
ecule over blood, cardiovascular system, gastrointestinal
system, kidney, liver, and lungs are shown in Figure 8 and
Figure 5 Functional site prediction using LIGSITEcsc. On the basis of interaction with the surrounding atoms, out of the three pockets predicted,
the pocket PKT 1032 with the best interaction result was identified as the possible functional site of the protein molecule.
Figure 6 Lead introduction in protein binding site. The molecule, 7-[5-O(hydroxy{[hydroxyl(phosphonooxy)phosphoryl]oxy}phosphoryl)pentofuranosyl]-
7H-pyrrolo[2,3-d]pyrimidin-5-amine was identified as the lead and using the Hex 6.3 [http://hex.loria.fr/] it was introduced into the protein
binding site.
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Figure 7 Ligand molecule and docking. Ligand molecule as build by the software LigBuilder version 1.3. (a) After docking using AutoDock
Tools-1.5.4 for the receptor of 1P9R. (b) Protein-ligand complex, ligand is shown in red color. (c) The conformation of ligand, 3-{(4S)-5-{[(1R)-1-cyclohexylethyl]
amino}-4-[(5S)-5-(prop-2-en-1-yl)cyclopent-1-en-1-yl]-1,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl}-1,2-dideoxy-b-L-erythro-hex-1-en-3-ulofuranosyl
(C28H44N4O3) with PilF protein has binding energy of −8.10 kcal M
−1 and inhibitory constant of 1.16 μM, the best docked ligand molecule.
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v5.0.0.184). The software facilitates in determining specific
structural toxicophores that are responsible for the organ-
specific toxic effect on the following: blood, cardiovascular
system, gastrointestinal system, kidney, liver, and lungs.
These fragmental contribution maps illustrate the role of
individual atoms and fragments of the ligand in a color-
coded manner; red color indicates a positive contribution
to the final predicted value or toxic action whereas green
color means the atom/fragment has a negative coeffi-
cient in the regression equation i.e., unrelated to the
health effects under investigation. These estimates are
based on data from over 100,000 compounds from chro-
nic, sub-chronic, and acute toxicity and carcinogenicityTable 2 Molecular properties of the ligand determined by




No. of hydrogen bond donors 4
No. of hydrogen bond acceptors 7
Topological polar surface area 91.042
No. of rotatable bonds 8studies with specific to particular organ systems. Evalu-
ation of the safety of new chemicals and pharmaceuticals
requires the combination of information from various
sources (e.g., in silico, in vitro, and in vivo) to provide an
assessment of risk to human health and the environment
[12], but in silico techniques can enable compounds to be
deselected earlier in development, thereby limiting the
need for animal testing. Previously, it has been proved that
in silico drug design is a potent tool to screen a drug and
virtually suggests its efficiency and any type of associated
health hazards before evaluating the same in vitro [13]
and/or in vivo [14]. Therefore, it is more likely that in the
future, performing the wet lab experiments involving
chemical synthesis of designed drug and testing the sameTable 3 Molecular Bioactivities of the ligand determined
by Molinspiration property engine v2011.04
Values
GPCR ligand 0.16
Ion channel modulator −0.13
Kinase inhibitor 0.03
Nuclear receptor ligand 0.09
Protease inhibitor 0.10
Enzyme inhibitor 0.14
Figure 8 The fragmental contribution maps of ligand on (a) blood, (b) cardiovascular system, (c) gastrointestinal system, (d) kidney, (e) liver, and
(f) lungs. These maps illustrate the role of individual atoms and fragments of the ligand in a color-coded manner; red color indicates a positive
contribution to the toxicity whereas green color means the atom/fragment has a no relevant effect.
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results.
Conclusions
The homology modeling of PilF protein of the N. menin-
gitidis Z2491strain based on the crystal structure of
chain A of Vibrio cholerae Putative Ntpase Epse [PDB:
1P9R] was performed. Using a structure-based drug
designing method, a potent inhibitor molecule was




the active site of PilF resulted in lowest binding energy
signifying highest binding affinity. The in silico ADME
and toxicity analysis confirmed its drug likeness and no
predicted health hazard. Also, it can be expected that this
study will be helpful in forming a base regarding themodeling of PilF protein and the development of anti-
meningococcal drugs.
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